Sanofi: Oddo BHF maintains 'buy' rating
(CercleFinance.com) - On Wednesday morning an Oddo BHF analyst confirmed a "buy" recommendation on the Sanofi share, noting more ambitious bets so as not to miss a second wave of innovation, after the group's R&D day.
The momentum over the next 5 years seems to be well underway, although it needs to be confirmed in the near term by clinical results over the next few months. Oddo said that yesterday's presentation confirmed its initial feeling on the LT vision that management wants to instill in the company. In particular, analysts appreciate this stance towards a more ambitious science strategy, with the desire to build new development platforms.
Oddo BHF therefore confirms its target price of 108 euros for the share, meaning upside potential of 16%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.